Complementary genetic and pharmacologic approaches were used to demonstrate that inhibition of the transcriptional regulator HES1 increases differentiation and impairs in vitro growth in the pediatric cancer rhabdomyosarcoma. This evidence concerns the gene HES1 and rhabdomyosarcoma.